South Korea · Delayed Price · Currency is KRW SK Biopharmaceuticals Statistics
Total Valuation
KRX:326030 has a market cap or net worth of KRW 6.88 trillion. The enterprise value is 6.55 trillion.
| Market Cap | 6.88T |
| Enterprise Value | 6.55T |
Important Dates
The next estimated earnings date is Wednesday, February 3, 2027.
| Earnings Date | Feb 3, 2027 |
| Ex-Dividend Date | n/a |
Share Statistics
KRX:326030 has 78.31 million shares outstanding.
| Current Share Class | 78.31M |
| Shares Outstanding | 78.31M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 10.63% |
| Float | 39.05M |
Valuation Ratios
The trailing PE ratio is 17.17 and the forward PE ratio is 18.16. KRX:326030's PEG ratio is 0.84.
| PE Ratio | 17.17 |
| Forward PE | 18.16 |
| PS Ratio | 7.96 |
| PB Ratio | 6.71 |
| P/TBV Ratio | 6.84 |
| P/FCF Ratio | 28.51 |
| P/OCF Ratio | 27.61 |
| PEG Ratio | 0.84 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.32, with an EV/FCF ratio of 27.12.
| EV / Earnings | 16.28 |
| EV / Sales | 7.58 |
| EV / EBITDA | 22.32 |
| EV / EBIT | 23.60 |
| EV / FCF | 27.12 |
Financial Position
The company has a current ratio of 2.72, with a Debt / Equity ratio of 0.05.
| Current Ratio | 2.72 |
| Quick Ratio | 2.15 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.15 |
| Debt / FCF | 0.20 |
| Interest Coverage | 54.31 |
Financial Efficiency
Return on equity (ROE) is 47.92% and return on invested capital (ROIC) is 44.59%.
| Return on Equity (ROE) | 47.92% |
| Return on Assets (ROA) | 15.98% |
| Return on Invested Capital (ROIC) | 44.59% |
| Return on Capital Employed (ROCE) | 27.68% |
| Weighted Average Cost of Capital (WACC) | 7.91% |
| Revenue Per Employee | 3.50B |
| Profits Per Employee | 1.63B |
| Employee Count | 246 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 0.51 |
Taxes
| Income Tax | -102.70B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.22% in the last 52 weeks. The beta is 0.66, so KRX:326030's price volatility has been lower than the market average.
| Beta (5Y) | 0.66 |
| 52-Week Price Change | -31.22% |
| 50-Day Moving Average | 79,118.00 |
| 200-Day Moving Average | 91,532.00 |
| Relative Strength Index (RSI) | 66.32 |
| Average Volume (20 Days) | 222,525 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KRX:326030 had revenue of KRW 861.34 billion and earned 400.96 billion in profits. Earnings per share was 5,119.90.
| Revenue | 861.34B |
| Gross Profit | 809.49B |
| Operating Income | 303.22B |
| Pretax Income | 289.21B |
| Net Income | 400.96B |
| EBITDA | 319.12B |
| EBIT | 303.22B |
| Earnings Per Share (EPS) | 5,119.90 |
Balance Sheet
The company has 381.87 billion in cash and 48.83 billion in debt, with a net cash position of 333.05 billion or 4,252.74 per share.
| Cash & Cash Equivalents | 381.87B |
| Total Debt | 48.83B |
| Net Cash | 333.05B |
| Net Cash Per Share | 4,252.74 |
| Equity (Book Value) | 1.02T |
| Book Value Per Share | 13,047.10 |
| Working Capital | 554.94B |
Cash Flow
In the last 12 months, operating cash flow was 248.48 billion and capital expenditures -7.82 billion, giving a free cash flow of 240.66 billion.
| Operating Cash Flow | 248.48B |
| Capital Expenditures | -7.82B |
| Depreciation & Amortization | 15.90B |
| Net Borrowing | -32.31B |
| Free Cash Flow | 240.66B |
| FCF Per Share | 3,072.98 |
Margins
Gross margin is 93.98%, with operating and profit margins of 35.20% and 46.55%.
| Gross Margin | 93.98% |
| Operating Margin | 35.20% |
| Pretax Margin | 33.58% |
| Profit Margin | 46.55% |
| EBITDA Margin | 37.05% |
| EBIT Margin | 35.20% |
| FCF Margin | 27.94% |
Dividends & Yields
KRX:326030 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 5.82% |
| FCF Yield | 3.51% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Analyst Forecast
The average price target for KRX:326030 is 131,230.77, which is 49.30% higher than the current price. The consensus rating is "Buy".
| Price Target | 131,230.77 |
| Price Target Difference | 49.30% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | 23.86% |
| EPS Growth Forecast (3Y) | 26.29% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
KRX:326030 has an Altman Z-Score of 14.31 and a Piotroski F-Score of 6.
| Altman Z-Score | 14.31 |
| Piotroski F-Score | 6 |